Document is current
Any future updates will be listed below
-
Authors
Mangues-Bafalluy, Irene https://orcid.org/0000-0001-5691-7991
Bernardez, Beatriz https://orcid.org/0000-0001-6579-4903
Martínez-Sesmero, José Manuel https://orcid.org/0000-0003-2226-8334
Navarro-Ruiz, Andres https://orcid.org/0000-0001-7009-280X
Martín-Conde, Maria Teresa https://orcid.org/0000-0002-7918-7036
Rubio-Salvador, Ana Rosa
Rius-Perera, Judith
Gilabert-Sotoca, Marta
Domínguez López, Marta
Callejo Mellén, Angel
-
Funding
Funding for this research was provided by:
AstraZeneca Farmacéutica Spain (Not applicable, Not applicable)
- License Information
-
More Information
Article History
Received: 1 June 2025
Accepted: 30 June 2025
First Online: 1 August 2025
Declarations
:
: IMB has been advisory board member for Seagen; has received consulting honorarium from Janssen, Gilead and speaker honorarium from MSD, GSK. BB has received payments for lectures, attendance to congresses, travel to courses and congresses, advisory boards, participation in working groups, etc., in the last few years from: Astra Zeneca, BMS, Merck, MSD, Novartis, Astellas, Sanofi Pfizer Takeda, GSK, Pharmamar, Daiichi Sankyo, Amgen, Seagen, Ipsen. JMMS has received consulting honorarium from AZ, Pfizer, Janssen, UCB and speaker honorarium from Roche and GSK. ANR has received consulting honorarium from Astra, UCB and speaker honorarium from Roche. ARRS has been advisory board member for GSK; has received consulting honorarium from Janssen, Lilly, AMGEN; and has received speaker honorarium from MSD, GSK. MDL and ACM are full-time employees of AstraZeneca Farmacéutica Spain. MTMC, JRP and MGS report no conflict of interest.
: This study was approved by the Ethics Committee for Research with Medicines from Galicia (Santiago de Compostela, Spain),
: All patients provided written informed consent.
: Not applicable.
